Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Casimersen and Golodirsen Extension in DMD
NCT03532542Phase 3Terminated
- Sponsor
- Sarepta Therapeutics
- Start
- Aug 2018
- Primary completion
- Jul 2023
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 13
01
Overview
A Phase 3 trial of casimersen, golodirsen in Duchenne muscular dystrophy (DMD), sponsored by Sarepta Therapeutics. Started Aug 2018; status: terminated.
02
Drugs
casimersengolodirsen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT03532542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03532542.